BG Medicine Reports 47 Percent Q4 Revenue Drop

Reporting for the first time as a publicly traded firm, BG Medicine said that automated versions of its recently FDA-cleared galectin-3 test for heart failure are anticipated to launch internationally by the end of the year and in the US sometime next year.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories